Peter Savas

10.0k total citations · 5 hit papers
49 papers, 4.3k citations indexed

About

Peter Savas is a scholar working on Oncology, Immunology and Cancer Research. According to data from OpenAlex, Peter Savas has authored 49 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 15 papers in Immunology and 14 papers in Cancer Research. Recurrent topics in Peter Savas's work include Cancer Immunotherapy and Biomarkers (27 papers), Immunotherapy and Immune Responses (13 papers) and Cancer Genomics and Diagnostics (11 papers). Peter Savas is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), Immunotherapy and Immune Responses (13 papers) and Cancer Genomics and Diagnostics (11 papers). Peter Savas collaborates with scholars based in Australia, Belgium and United States. Peter Savas's co-authors include Sherene Loi, Roberto Salgado, Phillip K. Darcy, Stephen J. Luen, Christos Sotiriou, Carsten Denkert, Balaji Virassamy, Mark J. Smyth, Zhi L. Teo and Paul A. Beavis and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Peter Savas

49 papers receiving 4.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

2017 662 citations Andrew Rowan, Nnennaya Kanu et al. profile →
Clinical relevance of host immunity in breast cancer: from TILs to the clinic

2015 638 citations Peter Savas, Roberto Salgado et al. Nature Reviews Clinical Oncology profile →
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

2015 432 citations Roberto Salgado, Peter Savas et al. profile →
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

2019 412 citations Imran G. House, Peter Savas et al. Clinical Cancer Research profile →
Towards targeting the breast cancer immune microenvironment

2024 119 citations Michael A. Harris, Peter Savas et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Savas Australia	23	3.2k	1.7k	1.1k	1.0k	1.0k	49	4.3k
Maria Vittoria Dieci Italy	36	3.1k 1.0×	750 0.4×	1.6k 1.4×	1.1k 1.0×	1.1k 1.1×	154	4.5k
Daniela S. Thommen Netherlands	18	3.2k 1.0×	2.5k 1.5×	501 0.5×	971 0.9×	680 0.7×	38	4.5k
Samer Al‐Saad Norway	36	2.3k 0.7×	1.3k 0.7×	1.3k 1.2×	1.7k 1.7×	1.2k 1.2×	66	4.3k
Viswam S. Nair United States	21	1.5k 0.5×	1.3k 0.8×	781 0.7×	1.1k 1.1×	1.1k 1.1×	44	3.4k
Laurence Buisseret Belgium	21	2.6k 0.8×	1.6k 1.0×	589 0.5×	684 0.7×	657 0.7×	65	3.6k
Sean P. Pitroda United States	33	1.8k 0.5×	933 0.5×	677 0.6×	1.1k 1.1×	1.0k 1.0×	94	3.4k
James S. Wilmott Australia	36	4.4k 1.4×	2.4k 1.4×	798 0.7×	2.8k 2.7×	1.0k 1.0×	139	6.4k
Marleen Kok Netherlands	30	2.3k 0.7×	953 0.6×	887 0.8×	1.1k 1.1×	817 0.8×	90	3.6k
Emma C. Paish United Kingdom	26	2.7k 0.8×	1.3k 0.8×	1.2k 1.1×	1.2k 1.2×	538 0.5×	43	4.1k
Hee Jin Lee South Korea	33	1.6k 0.5×	817 0.5×	1.0k 0.9×	1.3k 1.3×	453 0.5×	116	3.3k

Countries citing papers authored by Peter Savas

Since Specialization

Citations

This map shows the geographic impact of Peter Savas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Savas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Savas more than expected).

Fields of papers citing papers by Peter Savas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Savas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Savas. The network helps show where Peter Savas may publish in the future.

Co-authorship network of co-authors of Peter Savas

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Savas. A scholar is included among the top collaborators of Peter Savas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Savas. Peter Savas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luen, Stephen J., Peter Savas, Roswitha Kammler, et al.. (2025). Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials. JCO Precision Oncology. 9(9). e2400599–e2400599. 1 indexed citations

Virassamy, Balaji, Stephen J. Luen, Peter Savas, et al.. (2024). Sustained lymphocyte decreases after treatment for early breast cancer. npj Breast Cancer. 10(1). 94–94. 2 indexed citations

Harris, Michael A., et al.. (2024). The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments. Trends in cancer. 10(6). 490–506. 18 indexed citations

Teo, Zhi L., Mark J. O’Connor, Christopher Mintoff, et al.. (2023). Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer. npj Breast Cancer. 9(1). 68–68. 14 indexed citations

Savas, Peter, Stephen J. Luen, Elizabeth F. Blackley, et al.. (2022). Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. Cancer Discovery. 12(9). 2058–2073. 38 indexed citations

Mooi, Jennifer, Fiona Chionh, Peter Savas, et al.. (2021). Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. Clinical Cancer Research. 27(8). 2159–2167. 12 indexed citations

Savas, Peter, Roberto Salgado, & Sherene Loi. (2021). Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. Breast Cancer Research and Treatment. 189(3). 599–606. 12 indexed citations

Luen, Stephen J., Rebecca Asher, Chee Khoon Lee, et al.. (2020). Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Annals of Oncology. 31(10). 1359–1365. 4 indexed citations

Byrne, Ann, Peter Savas, Sneha Sant, et al.. (2020). Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nature Reviews Clinical Oncology. 17(6). 341–348. 211 indexed citations

10.

Bergin, Alice R.T., Stephen J. Luen, Peter Savas, et al.. (2019). Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2‐positive metastatic breast cancer: An Australian case series. Asia-Pacific Journal of Clinical Oncology. 15(6). 377–382. 1 indexed citations

11.

House, Imran G., Peter Savas, Junyun Lai, et al.. (2019). Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research. 26(2). 487–504. 412 indexed citations breakdown →

12.

Schmid, Peter, Delphine Loirat, Peter Savas, et al.. (2019). Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Research. 79(13_Supplement). CT049–CT049. 42 indexed citations

13.

Young, Richard J., Mathias Bressel, Sandro Porceddu, et al.. (2019). Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. Oral Oncology. 101. 104516–104516. 20 indexed citations

14.

Luen, Stephen J., Peter Savas, Stephen B. Fox, Roberto Salgado, & Sherene Loi. (2017). Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 49(2). 141–155. 106 indexed citations

15.

Teo, Zhi L., Sathana Dushyanthen, Franco Caramia, et al.. (2017). Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. Cancer Research. 77(22). 6340–6352. 148 indexed citations

16.

Dushyanthen, Sathana, Zhi L. Teo, Franco Caramia, et al.. (2017). Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nature Communications. 8(1). 606–606. 96 indexed citations

17.

Nolan, Emma, Peter Savas, Antonia N. Policheni, et al.. (2017). Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer. Science Translational Medicine. 9(393). 214 indexed citations

18.

Mayer, Ingrid A., Rebecca Dent, Tira J. Tan, Peter Savas, & Sherene Loi. (2017). Novel Targeted Agents and Immunotherapy in Breast Cancer. American Society of Clinical Oncology Educational Book. 37. 65–75. 5 indexed citations

19.

Savas, Peter, Zhi L. Teo, Christophe Lefèvre, et al.. (2016). The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE”. PLoS Medicine. 13(12). e1002204–e1002204. 83 indexed citations

20.

Lönnstedt, Ingrid, Franco Caramia, Jason Li, et al.. (2014). Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. Genome biology. 15(9). 470–470. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact